Skip to main content
Equibles

ADAG · Adagene Inc.

Track ADAG — free

Use ADAG with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ADAG.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.40 +0.09 (+2.72%) At close · Sep 11
Rebalance outlook locked
Market Cap
$228.29M
Shares
67.14M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$3.40 Open$3.36 Day$3.24–3.48 52W close$1.41–4.78 Avg vol 30d232K Short int2.1M · 3.1% float · 8.1d Short vol64% DataFeb 2021–Sep 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+45.3%
Trailing year
Short interest
3.1%
Latest settlement · 8.1 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Very Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.58
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +4%
above
Price vs 50-day avg −10%
below
RSI (14) 40
neutral
MACD trend Negative
52-week position 59%
mid-range
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Weak
1-month return −9%
trailing
6-month return −6%
trailing
YTD return +80%
this year
Relative strength −24%
vs S&P · 6-mo
Sentiment
smart money
Very Bullish
Trend (MA cross) No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+40% holders QoQ · +16 funds added
Insider flow Accumulating
Net +$92.3K over 90 days · 0% sells
Short interest Falling
3.09% of float · ▼ -1.8% MoM · 8.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
35 holders — near 3-yr high, broad support
Squeeze score 58
elevated · 0–100
Fundamentals
Excellent
Revenue growth +7333%
Y/Y
EPS growth +49%
Y/Y
Buyback $30.0M
authorized
Balance sheet $72.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 89%
annualized · 1-yr
Max drawdown −40%
past year
ATR 8.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 3 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+4% Bullish
Price vs 50-day avg
−10% Bearish
RSI (14)
40 Neutral
MACD trend
Negative Bearish
52-week position
59% Neutral
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross) No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+40% holders QoQ · +16 funds added
Insider flow Accumulating
Net +$92.3K over 90 days · 0% sells
Short interest Falling
3.09% of float · ▼ -1.8% MoM · 8.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
35 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $3 · 59% Range high $5
vs 200-day avg +4% vs 50-day avg -10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ADAG
Adagene Inc.
this stock
$228.29M +79.9% +7332.8% — 3.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.22B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
35
% held
28.7%
Net QoQ
+16.0M sh
Top holder
Jupiter Topco LLC
Held Float
View
Held by Funds
Fund positions
2
View
Short & Settlement
Short Interest Falling
Shares short
2.1M
Days to cover
8.1d
Change
-38.5K sh
View
Short Volume
Short vol %
64%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
9.6K
Value
$40.5K
As of
Aug 6, 2026
View
Off-Exchange
Off-exchange %
62.5%
Week of
Aug 3, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$92.3K
Buyers / Sellers
2 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$7.7M
Net income (FY)
$-17.6M
EPS diluted
$-0.30
View
Buybacks
Authorized · 2 programs
$30.0M
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 10, 2026
This year
10
View
Proposed Sales
Value
$158.0K
Shares
40.0K
Filed
Aug 19, 2026
View

Performance

5D 20D 120D MTD YTD
ADAG -7.9% -8.6% -6.3% -3.1% +79.9%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -6.7% -6.9% -24.2% -2.8% +67.8%

Capital returns

Buyback programs · 2 active · as of Jun 29, 2022
Authorized (total)
$30.00M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1818838 CUSIP 005329107 13F (30d) 17 filings 17 filers Visit website Investor relations